No Data
No Data
PepGen Announces Presentations at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference
PepGen Pauses Phase II DMD Trial to Review Safety Data
PepGen to Pause Study in Duchenne Muscular Dystrophy; Shares Down Pre-Bell
PepGen to Participate in Upcoming Investor Conferences
Express News | PepGen Inc - No New Safety Issues Observed in Pgn-Edo51 Program
Express News | PepGen Inc - Data From 10 Mg/Kg Cohort Expected in Q3 2025